Yu Dechao

May 31, 2020

Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT® (Sintilimab Injection) in the Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

May 31, 2020

Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma

Dec 01, 2019

Innovent Presents Co-developed Cancer-Fighting Tyvyt(R) (Sintilimab Injection) at CIIE 2019 with Eli Lilly

Oct 04, 2019

Innovent Biologics Announces a New Placement Raised HK$2,351.33 Million

Aug 05, 2019

Innovent and Shenogen Announce Collaboration to Evaluate Tyvyt® (Sintilimab injection) in Combination with SNG1005 for the Treatment of Patients with Advanced Cancer

Jun 03, 2019

Innovent Provides Update on Sintilimab in Combination with CAPOX for First-Line Treatment of Patients with Gastric or Gastroesophageal Junction Carcinoma (GC/GEJC)

Jun 03, 2019

Innovent Provides Updates on Extended Follow-up on Sintilimab for Relapsed/Refractory Classical Hodgkin's Lymphoma

Jun 03, 2019

Innovent Provides Update on ctDNA in Predicting Response and Resistance by Anti-PD-1 Therapy in Chinese Relapsed/Refractory Classical Hodgkin Lymphoma

May 15, 2019

Innovent Will Provide Key Results Update of Several Clinical Studies at 2019 ASCO Annual Meeting